Newsfeeds - Spark Newswire

4 minute read

45 Biggest Movers From Yesterday

Today, 3:29 PM

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.

ADIL

3 minute read

Terns Announces Initiation Of Patient Dosing In AVIATION Phase 1b NASH Clinical Trial Of VAP-1 Inhibitor TERN-201

By Bill Haddad

Today, 3:29 PM

TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH Sustained VAP-1 inhibition with TERN-201 may make it suitable for co-administration with other

TERN

5 minute read

The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO

By Shanthi Rexaline

Today, 3:29 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15)

ACHL

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:29 PM

Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).

AMC

1 minute read

Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist

By Vandana Singh

Today, 3:29 PM

Terns Pharmaceuticals Inc (NASDAQ:TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR)…

TERN

1 minute read

News

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

By Benzinga Newsdesk

Today, 3:29 PM

First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus, and both a differentiated pruritus and lipid profile in patients with NASH First 12-week controlled trial in patients with NASH

TERN